|1.||Coronary Disease (Coronary Heart Disease)
|2.||Type 2 Diabetes Mellitus (MODY)
|5.||Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
|1.||Matsunaga, Akira: 7 articles (04/2014 - 02/2006)|
|2.||Schwandt, P: 7 articles (06/2002 - 05/2000)|
|3.||Klingel, Reinhard: 6 articles (05/2015 - 06/2003)|
|4.||Saito, Takao: 6 articles (04/2014 - 02/2002)|
|5.||Parhofer, K G: 6 articles (06/2002 - 05/2000)|
|6.||Kobayashi, Junji: 5 articles (01/2014 - 10/2004)|
|7.||Yamashita, Shizuya: 5 articles (09/2013 - 06/2003)|
|8.||März, W: 5 articles (05/2004 - 05/2000)|
|9.||Heigl, Franz: 4 articles (05/2015 - 12/2009)|
|10.||Titov, V N: 4 articles (01/2014 - 07/2005)|
08/01/1983 - "The serial observations of the lipoprotein-lipid profiles were very useful for detecting the progressive changes in lipoproteins which occurred during the course of diseases, particularly in cases of secondary hyperlipoproteinemia. "
08/01/1986 - "These studies, using normal lipoproteins, do not preclude the possibility that lipoproteins from patients with type IIa, IIb, or IV hyperlipoproteinemia may be genetically abnormal or may function pathologically, resulting in an effect on thrombolysis."
08/01/1986 - "The effect of hyperlipoproteinemia on thrombolysis: in vitro studies using purified lipoproteins from normolipemic donors."
11/01/1985 - "This study indicates plasma lipoprotein abnormalities in Type V hyperlipoproteinemia and may suggest that depressed platelet aggregation and release in these patients are a result of this normal lipoprotein pattern."
10/21/1984 - "[New results of studies of plasma lipoprotein metabolism and the pathogenesis of hyperlipoproteinemias]."
06/01/2000 - "The objective of this study was to examine the relation between RLP-triglyceride (RLP-TG) to RLP-cholesterol (RLP-C) ratio and particle size distribution in RLP-C profiles from patients with hyperlipoproteinemia by HPLC. "
01/01/1979 - "Further catamnestic studies are needed to judge the values of cord blood cholesterol estimations in screening for familial hyperlipoproteinemias. "
01/01/1979 - "In vivo studies have shown abnormalities in cholesterol and bile acid metabolism in primary hyperlipoproteinemia (HLP). "
11/01/2004 - "The univariate analysis showed a significant relation between reocclusion and PAOD stage, hyperlipoproteinemia, and total cholesterol level and erythrocyte sedimentation rate (ESR), respectively. "
04/01/2003 - "In subjects with Type III hyperlipoproteinemia, alpha-epoxy cholesterol was mainly in CM/RM. "
09/01/1979 - "Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy."
12/01/1994 - "[Clofibrate treatment of hyperlipoproteinemia]."
08/01/1983 - "The results permit the conclusion that the use of clofibrate for the long-term treatment of hyperlipoproteinemia is still justified. "
11/01/1981 - "It is concluded that clofibrate is a strong hypolipidemic drug for the treatment of type III hyperlipoproteinemia, which does not lose efficacy even after 7 years of use."
11/01/1981 - "In this retrospective study we report the results of treatment with clofibrate during at least 7 years in 9 patients with severe type III hyperlipoproteinemia. "
|4.||Lovastatin (Mevacor)FDA LinkGeneric
01/01/1989 - "Thus, lovastatin is a highly effective and well tolerated hypolipidemic drug for the treatment of patients with IHD and hyperlipoproteinemia."
01/01/1992 - "I. Efficacy of lovastatin in the treatment of hyperlipoproteinemia]."
09/01/1990 - "This study reviews the progress of 56 consecutive patients with type IIa and IIb hyperlipoproteinemia following treatment with lovastatin. "
01/01/1990 - "All the patients suffered from primary non-familial hyperlipoproteinemia (of the IIa and IIb types) and were entered into the placebo-controlled studies of the effectiveness of lovastatin. "
02/01/1995 - "After one year of treatment, low-dose (20 mg/d) lovastatin achieved continued efficacy without tachyphylaxis in 36 patients with Type IIa or IIb hyperlipoproteinemia. "
12/06/1980 - "[The therapeutic efficacy of bezafibrate in hyperlipoproteinemias of various types]."
06/29/1985 - "These findings show that bezafibrate affords safe and effective long-term treatment of patients with hyperlipoproteinemia."
01/01/1990 - "Long lasting efficacy of Bezalip retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia."
06/29/1985 - "Bezafibrate, a new hypolipidemic agent, was evaluated in a single blind, placebo-controlled study lasting 14 months to 3 years in 40 patients with primary hyperlipoproteinemia of various types (23 patients with type II, 15 with type IV and 2 with type V). "
01/01/1992 - "The efficacy and safety of bezafibrate were evaluated in 83 patients with type IIa, IIb, or IV hyperlipoproteinemia. "
01/01/2007 - "No statistically significant correlation was observed either between changes in PON1 activity and HDL, HDL2, HDL3 and LDL cholesterol and triglyceride levels, or between their first differences in patients with both type IIa and IIb hyperlipoproteinemia. "
03/01/1994 - "However, sera from 16 patients with FDB stimulated less cell proliferation than did sera from patients with type IIa hyperlipoproteinemia with equal LDL-cholesterol concentrations. "
11/27/1987 - "In type II B hyperlipoproteinemia, there is a mean decrease in low-density lipoprotein cholesterol for all patients studied. "
10/22/1983 - "[Value of LDL-cholesterol determination in hyperlipoproteinemias]."
12/01/1976 - "Bile acid-binding resins, currently used for the treatment of Type II hyperlipoproteinemia, decrease LDL cholesterol by 25 to 35 per cent. "
|7.||Gemfibrozil (Lopid)FDA LinkGeneric
04/01/1996 - "We therefore conducted a double-blind, placebo-controlled, crossover study of gemfibrozil treatment on fibrinolytic function in 21 men with combined hyperlipoproteinemia. "
04/01/1996 - "Gemfibrozil treatment of combined hyperlipoproteinemia. "
01/01/1995 - "A placebo-controlled crossover study was conducted to evaluate whether lipid-lowering with gemfibrozil (10 to 12 weeks) affects platelet function in vivo at rest and during mental stress in 21 men with combined hyperlipoproteinemia. "
01/01/1995 - "Gemfibrozil enhances platelet activity in patients with combined hyperlipoproteinemia."
01/01/1991 - "[Gemfibrozil in the treatment of hyperlipoproteinemias]."
|8.||Niacin (Nicotinic Acid)FDA LinkGeneric
12/01/1994 - "Nicotinic acid and derivatives are effective in numerous forms of hyperlipoproteinemia. "
08/15/1994 - "To evaluate the safety and efficacy of controlled-release niacin in patients with hyperlipoproteinemia. "
12/01/1994 - "[Nicotinic acid and derivatives for therapy of hyperlipoproteinemia]."
07/01/1991 - "Nicotinic acid for the treatment of hyperlipoproteinemia."
02/17/1978 - "With the increased dosage of nicotinic acid, one must expect a large "drop out" of these appropriate hyperlipoproteinemia patients because of the side-effects resulting from this particular treatment with nicotinic acid."
07/01/1999 - "Patients homozygous for apolipoprotein E2 are predisposed to type III hyperlipoproteinemia, and apoE2 may be protective against AD. "
04/26/1996 - "Incomplete dominance of type III hyperlipoproteinemia is associated with the rare apolipoprotein E2 (Arg136-->Ser) variant in multigenerational pedigree studies."
07/01/2013 - "The lipid profiles showed type III hyperlipoproteinemia and phenotypic/genetic analyses revealed homozygosity of apoE2. "
01/01/2011 - "ApoE2 polymorphism is well known for its relationship to type III hyperlipoproteinemia, and the common apoE2 isoform is encoded by the R158C allele. "
05/01/2010 - "Homozygosis for APOE2 (E2-E2) is related to an increased incidence of type III hyperlipoproteinemia (HLP). "
|10.||Cholestyramine Resin (Questran)FDA LinkGeneric
08/01/1990 - "It is effective in treating patients with type IIa hyperlipoproteinemia and practically has no side effects as cholestyramine."
01/01/1991 - "The tolerance and efficacy of cholestyramine (12-16 gr/day) was evaluated in 19 patients with primary type-IIa hyperlipoproteinemia. "
10/01/1994 - "The aim of our study was the biochemical and functional examination of the liver during the therapy of familiar hyperlipoproteinemia by means of MevacorR (lovostatine) in comparison with the treatment by Vasosan S (cholestyramine). "
02/01/1984 - "Thus, although the sample size does not allow a definitive conclusion to be drawn, this study suggests that cholestyramine treatment retards the rate of progression of CAD in patients with Type II hyperlipoproteinemia."
09/01/1976 - "The extended use of diet and cholestyramine therapy in familial type II hyperlipoproteinemia was examined in patients who previously participated in a short-term, double-blind trial. "
|1.||Diet Therapy (Therapy, Diet)
09/01/1985 - "[Diet therapy of familial hyperlipoproteinemias in children]."
02/16/1976 - "[Diet therapy in primary hyperlipoproteinemia]."
06/07/1975 - "[Diet therapy in hyperlipoproteinemia]."
01/20/1974 - "[Diet therapy in hyperlipoproteinemias]."
01/01/1973 - "[Diet therapy of hyperlipoproteinemias from the diabetological viewpoint]."
08/01/1990 - "Massive plasmapheresis performed by the developed methods caused a significant improvement in the lipid spectrum, blood rheology, and microcirculation, which persisted for 1 to 6 months after plasmapheresis in relation to the type of hyperlipoproteinemia."
05/01/1987 - "Type V hyperlipoproteinemia and plasmapheresis."
02/01/1995 - "Within the framework of a seven-year clinical experience on treatment of severe hyperlipoproteinemia with/without associated coronary heart disease, with therapeutic plasmapheresis (APO B-100-containing lipoprotein-apheresis), we focused the present report on two young patients aged 7 and 11 years, respectively. "
01/01/1990 - "Effects of plasmapheresis on familial type III hyperlipoproteinemia associated with glomerular lipidosis, nephrotic syndrome and diabetes mellitus."
01/01/2002 - "Coli protein and human LDL can turn out to be useful in the future for purifying lipoproteins of a specific class and for administering plasmapheresis in patients with severe hyperlipoproteinemia."
|3.||Blood Component Removal (Apheresis)
04/01/2015 - "Lipid apheresis is at present well established in routine treatment of diverse hyperlipoproteinemias refractory to conventional dietary and medical regimens, especially in countries with high medical and socioeconomic standards. "
02/01/2007 - "The aim of this work is to arbitrate the incidence of side effects and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. "
02/01/2007 - "Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia."
12/01/2001 - "[Hyperlipoproteinemia and LDL apheresis. "
07/13/1998 - "[Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis]."
|4.||Combination Drug Therapy (Combination Chemotherapy)
04/01/1990 - "The results of this study demonstrate the potential usefulness of lovastatin in the therapy of type III hyperlipoproteinemia and indicate that, in selected patients who remain hypercholesterolemic on monotherapy with either clofibrate or lovastatin, combination drug therapy with both of these drugs is effective in further reducing plasma concentrations of total, VLDL, and LDL cholesterol.(ABSTRACT TRUNCATED AT 250 WORDS)"
08/01/1987 - "These results suggest that the oral administration of vitamin E (500 IU/day) is beneficial in hyperlipoproteinemia and offers a potential tool for treating the increased coronary heart disease risk."
12/01/1984 - "The oral administration of neomycin or niacin as single-drug therapy can significantly lower total and low-density lipoprotein cholesterol concentrations in patients with type II hyperlipoproteinemia. "
02/01/1987 - "The kinetics of chylomicron metabolism have been studied by measuring retinyl palmitate in chylomicrons and their remnants for 10-12 hr following oral administration of vitamin A and Lipomul in three groups of adult male subjects: A) normal plasma triglyceride levels (n = 7); B) endogenous hypertriglyceridemia (n = 12); C) apolipoprotein E (apoE) phenotype E2/2, with Type 3 hyperlipoproteinemia (n = 4) or normal plasma lipids (n = 1). "